RECRUITING Not applicable ClinicalTrials.gov

MitoQ to Improve Vascular Funciton in Preeclampsia

Sponsor: Medical College of Wisconsin • ClinicalTrials.gov ID: NCT07229261

Registry updated: 2026-10-02

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

Preeclampsia is a leading cause of maternal and neonatal morbidity and mortality. There is a lack of effective therapeutics for prevention or treatment. Our previous ex vivo work demonstrated that mitochondrial-antioxidants can reverse placental microvascular damage. Therefore, this study will evaluate whether MitoQ (Mitoquinol Mesylate, a mitochondrial-antioxidant) has the potential to restore vasodilation, improve placental function, and therefore promote pregnancy prolongation in patients with gestational hypertension (gHTN) and/or preeclampsia. This evaluation of clinical data, patient samples, and vascular function studies in patients with gHTN and/or preeclampsia could translate into a viable therapeutic option.

Interventions

Mitoquinol Mesylate (Dietary supplement)
Patients randomized to the intervention will receive 10mg of Mitoquinol Mesylate daily from enrollment until delivery.
Placebo (Other)
Patients randomized to the placebo groups will take 1 placebo capsule daily until delivery.

Eligibility criteria

Inclusion Criteria: * Inpatient Cohort * pregnant patients with a clinical diagnosis of preeclampsia with severe features * gestational age between 23+0 and 33+0 weeks' gestation * singleton pregnancy * age 18-50 years old * No indication for immediate delivery (e.g. the patient and their physician team have planned expectant management of preeclampsia with severe features * Able to consent and follow a 2-step commend * English speaking * Outpatient Cohort * Pregnant patients with a clinical diagnosis of preeclampsia without severe features or gestational hypertension * gestational age between 23+0 and 34+0 weeks gestation * singleton pregnancy * age 18-50 years old * No indication for immediate delivery * Planned outpatient management of preeclampsia * Able to consent and follow a 2-step commend * English speaking Exclusion Criteria: * Unable to stand from chair without physical assistance from another person (able to use assistive device). * History of blood clots in the extremities or any condition in which compression of the thigh or transient ischemia is contraindicated (i.e., wounds in the leg). * Chronic lasting symptoms (\> 6 months) of severe COVID-19 (i.e., hospitalization) * History of head trauma or concussion within the past 6 months * Comorbid neurological disorder * Peripheral vascular disease * Diagnosed myocardial infarction or arrhythmia in the previous year * Resting SBP ≥180 mmHg or DBP ≥ 100 mmHg * Other significant medical condition likely to influence study or jeopardize safety as assessed by the Primary Investigator

Conditions

Preeclampsia Pregnancy

Locations

Froedtert & the Medical College of Wisconsin — Milwaukee, Wisconsin, United States

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment